Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT00368108
First received: August 22, 2006
Last updated: May 13, 2013
Last verified: January 2013
Results First Received: October 23, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Parkinson's Disease
Interventions: Drug: 2 mg perampanel
Drug: 4 mg perampanel
Drug: placebo comparator

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Placebo The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
Perampanel 2mg The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
Perampanel 4mg The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampanel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.

Participant Flow:   Overall Study
    Placebo     Perampanel 2mg     Perampanel 4mg  
STARTED     251 [1]   251     250  
COMPLETED     187     198     182  
NOT COMPLETED     64     53     68  
Adverse Event                 38                 26                 44  
Abnormal Laboratory Value                 0                 0                 3  
Protocol Violation                 5                 9                 9  
Withdrawal by Subject                 9                 3                 5  
Lack of Efficacy                 7                 8                 5  
Physician Decision                 2                 0                 1  
Not Specified                 3                 7                 1  
[1] One subject had stopped medication prior to notifying staff. Remaining results will have 250.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Placebo The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
Perampanel 2mg The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
Perampanel 4mg The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampanel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
Total Total of all reporting groups

Baseline Measures
    Placebo     Perampanel 2mg     Perampanel 4mg     Total  
Number of Participants  
[units: participants]
  250     251     250     751  
Age, Customized  
[units: Participants]
       
<65 years     149     144     147     440  
≥ 65 years     101     107     103     311  
Gender  
[units: participants]
       
Female     86     87     86     259  
Male     164     164     164     492  
Race/Ethnicity, Customized  
[units: Participants]
       
White     233     239     240     712  
Black     4     2     1     7  
Asian     5     4     1     10  
Other     8     6     8     22  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data)   [ Time Frame: Baseline and Week 20 ]

2.  Secondary:   Mean Change From Baseline in Scale UPDRS Part II (ADL) Score in Total Daily OFF Time to Week 20 (Including LOCF Data)   [ Time Frame: Baseline and Week 20 ]

3.  Secondary:   Mean Change From Baseline in UPDRS Part III (Motor) Score in ON State (Hours) to Week 20 (Including LOCF Data)   [ Time Frame: Baseline and Week 20 ]

4.  Secondary:   Mean Change From Baseline in Total Daily ON Time (Without Dyskinesias or With Non-troublesome Dyskinesias) (Hours) to Week 20 (Including LOCF Data)   [ Time Frame: Baseline and Week 20 ]


  Serious Adverse Events
  Hide Serious Adverse Events

Time Frame From the time the subject signed the informed consent form to 30 days after the last dose of the study drug.
Additional Description Adverse events were assessed at clinical visits based on the subject's diary, vitals, weight, physical examination, neurological exam, and laboratory evaluations.

Reporting Groups
  Description
Placebo The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
Perampanel 2mg The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
Perampanel 4mg The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampanel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.

Serious Adverse Events
    Placebo     Perampanel 2mg     Perampanel 4mg  
Total, serious adverse events        
# participants affected / at risk     22/250 (8.80%)     12/251 (4.78%)     18/250 (7.20%)  
Blood and lymphatic system disorders        
Anaemia † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Cardiac disorders        
Atrial flutter † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Coronary artery disease † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Myocardial infarction † 1      
# participants affected / at risk     2/250 (0.80%)     1/251 (0.40%)     0/250 (0.00%)  
Myocardial ischaemia † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Angina Pectoris † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Cardio-Respiratory arrest † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Coronary artery occlusion † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Gastrointestinal disorders        
Constipation † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Large intestine perforation † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Oesophageal stenosis † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Small intestinal obstruction † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Crohn's disease † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Gastrointestinal haemorrhage † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Rectal haemorrhage † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
General disorders        
Non-cardiac chest pain † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     1/250 (0.40%)  
Chest pain † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Pain † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Infections and infestations        
Pneumonia † 1      
# participants affected / at risk     2/250 (0.80%)     0/251 (0.00%)     2/250 (0.80%)  
Cellulitis † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Urinary tract infection † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Injury, poisoning and procedural complications        
Fall † 1      
# participants affected / at risk     1/250 (0.40%)     1/251 (0.40%)     1/250 (0.40%)  
Femur fracture † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     1/250 (0.40%)  
Hip fracture † 1      
# participants affected / at risk     2/250 (0.80%)     0/251 (0.00%)     1/250 (0.40%)  
Wrist fracture † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Joint dislocation † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Stress fracture † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Metabolism and nutrition disorders        
Dehydration † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Musculoskeletal and connective tissue disorders        
Pain in extremity † 1      
# participants affected / at risk     1/250 (0.40%)     1/251 (0.40%)     0/250 (0.00%)  
Osteoarthritis † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Neoplasms benign, malignant and unspecified (incl cysts and polyps)        
Melanoma recurrent † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Bile duct cancer † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Prostate cancer † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Nervous system disorders        
Syncope † 1      
# participants affected / at risk     1/250 (0.40%)     1/251 (0.40%)     1/250 (0.40%)  
Cerebrovascular accident † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Memory Impairment † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Myasthenia gravis † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
ON and OFF phenomenon † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Quadriparesis † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Tremor † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Reversible ischaemic neurological deficit † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Tonic convulsion † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Psychiatric disorders        
Confusional state † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Hallucination † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Suicide attempt † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Delirium † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Hallucination, visual † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Major depression † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Renal and urinary disorders        
Nephrolithiasis † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Micturition urgency † 1      
# participants affected / at risk     1/250 (0.40%)     0/251 (0.00%)     0/250 (0.00%)  
Respiratory, thoracic and mediastinal disorders        
Dyspnoea † 1      
# participants affected / at risk     0/250 (0.00%)     0/251 (0.00%)     1/250 (0.40%)  
Surgical and medical procedures        
Hospitalization † 1      
# participants affected / at risk     0/250 (0.00%)     1/251 (0.40%)     0/250 (0.00%)  
Events were collected by systematic assessment
1 Term from vocabulary, MedDRA V. 10.1




  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Eisai Inc.
Organization: Eisai Call Center
phone: 888-422-4743


No publications provided


Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00368108     History of Changes
Other Study ID Numbers: E2007-A001-302
Study First Received: August 22, 2006
Results First Received: October 23, 2012
Last Updated: May 13, 2013
Health Authority: United States: Food and Drug Administration